Beta-lactam and Beta-lactamase Inhibitors Market Expected to Reach $34,170 Million by 2028

Beta-lactam and beta-lactamase inhibitor's market size was $27,126 million in 2018 and is projected to reach $34,170 million by 2028, growing at a CAGR of 2.3% from 2019 to 2028. The cephalosporin segment accounted for more than two-fifths of the total beta-lactam and beta-lactamase inhibitors market share in 2018.

Download Report Sample PDF @ https://www.alliedmarketresearch.com/request-sample/5427

Beta-lactam and beta-lactamase inhibitors are chemical compounds of natural or semi-synthetic or synthetic origin. They inhibit the growth of bacteria and protozoans.

The beta-lactam and beta-lactamase inhibitors market is expected to exhibit significant growth during the forecast period due to increased consumption in low and middle-income countries (LMICs) and a rise in the prevalence of infectious diseases. In addition, the development of novel approaches for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections and a large number of clinical trials, further supplement the market growth.

The beta-lactam and beta-lactamase inhibitors market is expected to exhibit significant growth during the forecast period due to the increased consumption in low- and middle-income countries (LMICs) and the rise in the prevalence of infectious diseases. In addition, the development of novel approaches for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections and a large number of clinical trials further drive the market growth.

However, the development of antibiotic resistance, driven by misuse of beta-lactam and beta-lactamase inhibitors and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, the discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.

Based on drug class, the market is categorized into penicillin, cephalosporin, carbapenem, monobactam, and combination. The combination segment is further categorized into penicillin/beta-lactamase inhibitors, cephalosporins/beta-lactamase inhibitors, and carbapenems/beta-lactamase inhibitors. The combination segment is projected to exhibit the highest growth during the forecast period. This is attributed to rising in the prevalence of antimicrobial resistance and increasing incidences of chronic diseases.

For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/5427

Asia-Pacific was the leading revenue contributor to the global beta-lactam and beta-lactamase inhibitors market in 2018 and is expected to remain dominant throughout the forecast period. This is attributed to an upsurge in the incidence of chronic diseases, an increase in the geriatric population, a rise in the consumption of antibiotics, and the availability of drugs over-the-counter without a prescription.

The report provides a comprehensive analysis of the key players operating in the global beta-lactam and beta-lactamase inhibitors market industry, namely, Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. The other players in the value chain include Hikma Pharmaceuticals, Melinta Therapeutics, Eli Lilly and Company, Shionogi, Inc., AstraZeneca plc, and others.

Key Findings of the Beta-lactam and Beta-lactamase Inhibitor Market:
1. Based on drug class, the cephalosporin segment was the major revenue contributor in 2018 and is anticipated to continue this trend during the forecast period.
2. Based on the diseased segment, its complicated intra-abdominal infection (cIAI) is expected to exhibit the highest CAGR with 4.8% during the forecast period.
3. Depending on route of administration, the oral segment was the largest revenue contributor in 2018 and expected to continue this trend from 2019 to 2028.
4. U.S. generated the highest revenue in the global beta-lactam and beta-lactamase inhibitors in 2018, accounting more than one-fifth of the global market in 2018.
5. LAMEA is estimated to grow at a highest CAGR during the forecast period.

Get detailed COVID-19 impact analysis on @ https://www.alliedmarketresearch.com/beta-lactam-and-beta-lactamase-inhibitors-market

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.